| Name | Title | Contact Details |
|---|
Gateway Community Health Center, Inc. is a community health center funded by the U.S. Department of Health and Human Services. The Center is a 501 (c) (3) private, non-profit corporation with a governing board of 15 directors whose responsibility is t...
High Deductible Health Plans Today is a Quincy, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Microliter is a Cutchogue, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DCPCA is a nonprofit health reform organization founded in 1996 by health care professionals who were concerned that the shortage of primary health care in the District was contributing to increasingly poor health outcomes for DC's most vulnerable residents. With a budget of $140,000 in seed money from the federal government's Bureau of Primary Care, Sharon Baskerville became DCPCA's first executive director in 1998. As DCPCA established itself in the late 1990s, District voters elected a new mayor and six new members of the DC Council. The improved political environment made it possible for the District's budget to emerge from direct federal control. Under these new conditions, DCPCA emerged as a health reform leader and quickly became the local voice promoting progressive health care financing and public policy, galvanizing political support at the local and federal levels.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.